Physician profile
Ivan Morrin
NPI 1104825934
$10,015.58
in general payments reported to CMS, 2019-2025
58 companies · $1,490 in 2025
The $1,490 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117 · 2020: $1,376 · 2021: $1,457 · 2022: $1,537 · 2023: $1,632 · 2024: $1,406 · 2025: $1,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,430 · Education: $97.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,430.46 |
| Education | $97.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,286.01 | 2021-2025 | |
| Novo Nordisk INC | $959.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $773.44 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $737.78 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $656.20 | 2019-2025 | Synjardy, Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals Lp | $557.07 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $514.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $391.21 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $334.20 | 2019-2023 | Trintellix |
| Amgen INC. | $269.15 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $254.77 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.42 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $223.17 | 2019-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $212.65 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $203.99 | 2020-2023 | Verquvo, Belsomra, Steglatro |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Morrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.